|
1
|
Soerjomataram I, Lortet-Tieulent J, Parkin
DM, Ferlay J, Mathers C, Forman D and Bray F: Global burden of
cancer in 2008: A systematic analysis of disability-adjusted
life-years in 12 world regions. Lancet. 380:1840–1850. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sobin L GM and Wittekind C: TNM
Classification of Malignant Tumours. 7th edition. Wiley-Blackwell;
Chichester: 2009
|
|
4
|
Van Cutsem E, Nordlinger B and Cervantes
A: ESMO Guidelines Working Group: Advanced colorectal cancer: ESMO
clinical practice guidelines for treatment. Ann Oncol. 21 Suppl
5:v93–v97. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wittekind C: 2010 TNM system: On the 7th
edition of TNM classification of malignant tumors. Pathologe.
31:331–332. 2010.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cirocchi R, Trastulli S, Abraha I,
Vettoretto N, Boselli C, Montedori A, Parisi A, Noya G and Platell
C: Non-resection versus resection for an asymptomatic primary
tumour in patients with unresectable stage IV colorectal cancer.
Cochrane Database Syst Rev: CD008997. 2012. View Article : Google Scholar
|
|
7
|
Ruo L, Gougoutas C, Paty PB, Guillem JG,
Cohen AM and Wong WD: Elective bowel resection for incurable stage
IV colorectal cancer: Prognostic variables for asymptomatic
patients. J Am Coll Surg. 196:722–728. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Venderbosch S, de Wilt JH, Teerenstra S,
Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME,
Mol L, Punt CJ and Koopman M: Prognostic value of resection of
primary tumor in patients with stage IV colorectal cancer:
Retrospective analysis of two randomized studies and a review of
the literature. Ann Surg Oncol. 18:3252–3260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferrand F, Malka D, Bourredjem A, Allonier
C, Bouché O, Louafi S, Boige V, Mousseau M, Raoul JL, Bedenne L, et
al: Impact of primary tumour resection on survival of patients with
colorectal cancer and synchronous metastases treated by
chemotherapy: Results from the multicenter, randomised trial
Federation Francophone de Cancérologie Digestive 9601. Eur J
Cancer. 49:90–97. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Poultsides GA, Servais EL, Saltz LB, Patil
S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD and Paty PB:
Outcome of primary tumor in patients with synchronous stage IV
colorectal cancer receiving combination chemotherapy without
surgery as initial treatment. J Clin Oncol. 27:3379–3384. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Schlag PM, Rougier P, Bechstein
WO, Primrose JN, et al: Perioperative chemotherapy with FOLFOX4 and
surgery versus surgery alone for resectable liver metastases from
colorectal cancer (EORTC Intergroup trial 40983): A randomised
controlled trial. Lancet. 371:1007–1016. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al: Perioperative FOLFOX4 chemotherapy and
surgery versus surgery alone for resectable liver metastases from
colorectal cancer (EORTC 40983): Long-term results of a randomised,
controlled, phase 3 trial. Lancet Oncol. 14:1208–1215. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lao VV and Grady WM: Epigenetics and
colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:686–700. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nagasaka T, Sasamoto H, Notohara K,
Cullings HM, Takeda M, Kimura K, Kambara T, MacPhee DG, Young J,
Leggett BA, et al: Colorectal cancer with mutation in BRAF, KRAS,
and wild-type with respect to both oncogenes showing different
patterns of DNA methylation. J Clin Oncol. 22:4584–4594. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wong JJ, Hawkins NJ and Ward RL:
Colorectal cancer: A model for epigenetic tumorigenesis. Gut.
56:140–148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Van Cutsem E, Kohne CH, Hitre E, Zaluski
J, Chien Chang CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Laurent-Puig P, Cayre A, Manceau G, Buc E,
Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, et al:
Analysis of PTEN, BRAF, and EGFR status in determining benefit from
cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin
Oncol. 27:5924–5930. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tol J, Nagtegaal ID and Punt CJ: BRAF
mutation in metastatic colorectal cancer. N Engl J Med. 361:98–99.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Final results from PRIME: Randomized phase 3
study of panitumumab with FOLFOX4 for first-line treatment of
metastatic colorectal cancer. Ann Oncol. 25:1346–1355. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Roth AD, Tejpar S, Delorenzi M, Yan P,
Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C,
et al: Prognostic role of KRAS and BRAF in stage II and III
resected colon cancer: Results of the translational study on the
PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 28:466–474.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hamilton SR and Aaltonen LA: Pathology and
genetics of tumours of the digestive systemWorld Health
Organization Classification of Tumours. IARCPress; Lyon: 2000
|
|
27
|
Seifert G, Brocheriou C, Cardesa A and
Eveson JW: WHO International Histological Classification of
Tumours. Tentative histological classification of salivary gland
tumours. Pathol Res Pract. 186:555–581. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nagasaka T, Koi M, Kloor M, Gebert J,
Vilkin A, Nishida N, Shin SK, Sasamoto H, Tanaka N, Matsubara N, et
al: Mutations in both KRAS and BRAF may contribute to the
methylator phenotype in colon cancer. Gastroenterology.
134(1950–1960): 1960. e12008.
|
|
29
|
Goel A, Nagasaka T, Hamelin R and Boland
CR: An optimized pentaplex PCR for detecting DNA mismatch
repair-deficient colorectal cancers. PLoS One. 5:e93932010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stillwell AP, Buettner PG and Ho YH:
Meta-analysis of survival of patients with stage IV colorectal
cancer managed with surgical resection versus chemotherapy alone.
World J Surg. 34:797–807. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Simpson-Herren L, Sanford AH and Holmquist
JP: Effects of surgery on the cell kinetics of residual tumor.
Cancer Treat Rep. 60:1749–1760. 1976.PubMed/NCBI
|
|
32
|
Fisher B, Gunduz N and Saffer EA:
Influence of the interval between primary tumor removal and
chemotherapy on kinetics and growth of metastases. Cancer Res.
43:1488–1992. 1983.PubMed/NCBI
|
|
33
|
Peeters CF, Westphal JR, de Waal RM,
Ruiter DJ, Wobbes T and Ruers TJ: Vascular density in colorectal
liver metastases increases after removal of the primary tumor in
human cancer patients. Int J Cancer. 112:554–559. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Peeters CF, de Waal RM, Wobbes T, Westphal
JR and Ruers TJ: Outgrowth of human liver metastases after
resection of the primary colorectal tumor: A shift in the balance
between apoptosis and proliferation. Int J Cancer. 119:1249–1253.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Scheer MG, Stollman TH, Vogel WV, Boerman
OC, Oyen WJ and Ruers TJ: Increased metabolic activity of indolent
liver metastases after resection of a primary colorectal tumor. J
Nucl Med. 49:887–891. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Umar A, Boland CR, Terdiman JP, Syngal S,
de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ,
Hamelin R, et al: Revised bethesda guidelines for hereditary
nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite
instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Imai K and Yamamoto H: Carcinogenesis and
microsatellite instability: The interrelationship between genetics
and epigenetics. Carcinogenesis. 29:673–680. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Boland CR, Thibodeau SN, Hamilton SR,
Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA,
Fodde R, Ranzani GN and Srivastava S: A National Cancer Institute
Workshop on Microsatellite Instability for cancer detection and
familial predisposition: Development of international criteria for
the determination of microsatellite instability in colorectal
cancer. Cancer Res. 58:5248–5257. 1998.PubMed/NCBI
|
|
39
|
Hutchins G, Southward K, Handley K, Magill
L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M,
Kerr D, et al: Value of mismatch repair, KRAS, and BRAF mutations
in predicting recurrence and benefits from chemotherapy in
colorectal cancer. J Clin Oncol. 29:1261–1270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Popat S, Hubner R and Houlston RS:
Systematic review of microsatellite instability and colorectal
cancer prognosis. J Clin Oncol. 23:609–618. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rajagopalan H, Bardelli A, Lengauer C,
Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis: RAF/RAS
oncogenes and mismatch-repair status. Nature. 418:9342002.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang L, Cunningham JM, Winters JL,
Guenther JC, French AJ, Boardman LA, Burgart LJ, McDonnell SK,
Schaid DJ and Thibodeau SN: BRAF mutations in colon cancer are not
likely attributable to defective DNA mismatch repair. Cancer Res.
63:5209–5212. 2003.PubMed/NCBI
|
|
43
|
Lochhead P, Kuchiba A, Imamura Y, Liao X,
Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt
JA, et al: Microsatellite instability and BRAF mutation testing in
colorectal cancer prognostication. J Natl Cancer Inst.
105:1151–1156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Taieb J, Zaanan A, Le Malicot K, Julié C,
Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, et
al: Prognostic effect of BRAF and KRAS mutations in patients with
stage III colon cancer treated with leucovorin, fluorouracil and
oxaliplatin with or without cetuximab: A post hoc analysis of the
PETACC-8 trial. JAMA Oncol. 1–11. 2016.PubMed/NCBI
|
